BASINGSTOKE, England and PHILADELPHIA, April 25 /PRNewswire/ --
- All Figures are in US$
Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to March 31, 2008.
Q1 2008 Financial Highlights - Product sales up 37% to $632m - New product sales(1) $216m, 34% of product sales (2007: 13%) - Total revenues up 33% to $702m - US GAAP Operating income up 15% to $163m - Non GAAP Operating income up 23% to $192m - US GAAP Earnings per ADS up 7% to $0.68 - Non GAAP Earnings per ADS up 5% to $0.74
(1) New product sales include DAYTRANA, DYNEPO, ELAPRASE, FOSRENOL, LIALDA/MEZAVANT and VYVANSE
Matthew Emmens, Chief Executive Officer, commented: